Browsing by Subject
Now showing items 1-1 of 1
-
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis
(Lippincott Williams & Wilkins, 2022-07)
Now showing items 1-1 of 1